Precision health company Helix announced on Monday that it is introducing a new comprehensive clinico-genomic dataset of more than 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, tirzepatide, liraglutide and dulaglutide.

The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+ sequencing profiles for 15,000 GLP-1 agonist treated patients combined with longitudinal and regularly refreshed EHR data including demographics, clinical diagnosis (T2D, CVD, kidney diseases, etc), major lab results and procedures, as well as insights from medical and mortality claims data.

James Lu, MD, PhD, Helix CEO, said: "The success of GLP-1 agonists like semaglutide and tirzepatide have created incredible advances in the treatment of cardiometabolic disease and obesity, and the demand for and uptake of these therapies are not slowing down anytime soon. Our registry has more than tripled in less than a year, and will continue to meet and even outpace usage trends, allowing insights from deep real-world data coupled with broad genomic data to play a key role in monitoring safety profiles, determining cost-effectiveness and improving treatment efficacy in select populations."